| TRAINEE’S CORNER |
|
| Year : 2020 | Volume
: 41
| Issue : 6 | Page : 889-892 |
|
|
Antibody drug conjugates
Stalin Bala1, Siva K Prasad2
1 Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
2 Department of Medical Oncology, Santhiram Medical College and General Hospital, Nandyal, Andhra Pradesh, India
Correspondence Address:
Dr. Siva K Prasad
Santhiram Medical College and General Hospital, Nandyal - 518 501, Andhra Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijmpo.ijmpo_313_20
|
|
|
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released, which finally leads to cell killing. Payloads are broadly divided into tubulin-disrupting agents and DNA-damaging agents. Most of the current ADCs utilize humanized mAbs, and fully human mAbs are under investigation. ADC development process is accelerated by better designing and bio-engineering methods. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
